[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Luebeck\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":272},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,40,66,88,109,131,153,179,199,228,248],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100638739","low-voltage-area-guided-catheter-ablation-and-svc-isolation-for-persistent-atrial-fibrillation-using-a-balloon-in-basket-pulsed-field-ablation-catheter-100638739",false,"NCT07587541","Low-VOLTage Area-Guided Catheter Ablation and SVC Isolation for Persistent Atrial Fibrillation Using a Balloon-in-Basket Pulsed Field Ablation Catheter","LowVOLT-AF Study: Low-VOLTage Areas-Guided Catheter Ablation and SVC Isolation for Persistent Atrial Fibrillation Using a Balloon-in-Basket Pulsed Field Ablation Catheter","LowVOLT-AF","Inclusion criteria\n\nParticipants must meet all the following criteria:\n\n1. Age ≥18 years\n2. Persistent AF, defined as continuous AF lasting at least 7 days\n3. Indication for catheter ablation according to the latest ESC guidelines\n4. Written informed consent\n\nExclusion criteria\n\nParticipants will be excluded if any of the following criteria apply:\n\n1. Inability or unwillingness to provide informed consent\n2. Continuous AF duration duration of ≥2 years\n3. Documented atrial tachycardia or atrial flutter\n4. Previous left atrial catheter ablation or cardiac surgery\n5. Planned cardiac surgery within the first 3 months after inclusion\n6. History of heart transplantation, current listing for transplantation, or planned cardiac assist device implantation\n7. Severe mitral or aortic valvular disease, according to the ESC guidelines\n8. Platelet count \\\u003C50,000 cells\u002Fmm³\n9. Body mass index \\>45 kg\u002Fm² or \\\u003C18 kg\u002Fm²\n10. Untreated thyroid dysfunction (patients may be included once hypothyroidism or hyperthyroidism is adequately treated)\n11. Absolute contraindication to oral anticoagulation\n12. Any comorbidity that limits life expectancy to \\\u003C1 year\n13. Active systemic infection (enrolment permitted after successful treatment)\n14. Women who are pregnant or breastfeeding\n15. Women of childbearing potential not using highly effective contraception (PEARL Index \\\u003C1%)\n16. End-stage renal disease (GFR \\\u003C15 ml\u002Fmin\u002F1.73 m2) or hepatic failure (Child Pugh C)\n17. Acutely decompensated heart failure (NYHA IV), inclusion is possible only after stabilization to a NYHA functional status better than IV\n18. Participation in another randomized controlled trial","ALL","18 Years",{"count":20,"type":21},618,"ESTIMATED","INTERVENTIONAL",[24],"NA","The primary objective of this study is to determine whether low-voltage areas (LVA)-guided catheter ablation combined with superior vena cava (SVC) isolation and pulmonary vein isolation (PVI), performed using the balloon-in-basket Volt™ pulsed field ablation PFA system, is superior to PVI alone using same technology in reducing arrhythmia recurrence at 6 and 12 months in patients with persistent AF and detectable significant LVAs on three-dimensional electroanatomical mapping.\n\nMoreover, the study will investigate, in a separate randomized cohort, the effect of adding SVC isolation to PVI using the balloon-in-basket Volt™ PFA system, compared with PVI alone, in patients with persistent AF without detectable significant LVAs during three-dimensional electroanatomical mapping.",[27],"Atrial Fibrillation (AF)","NOT_YET_RECRUITING","2026-05-15",{"date":31,"type":32},"2026-05-19","ACTUAL",{"date":34,"type":21},"2026-05-18",{"date":36,"type":21},"2029-11-01",{"name":38,"class":39},"University of Luebeck","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":48,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100458080","epidemiology-of-sexually-transmitted-infections-and-its-impact-on-female-infertility-100458080","NCT05244967","Epidemiology of Sexually Transmitted Infections and Its iMpAcT on fEmale Infertility","ESTIMATE","Inclusion Criteria:\n\n* 18-22 years\n* informed consent\n\nExclusion Criteria:\n\n* pregnancy\n* sterilization\n* not capable of giving informed consent",true,"FEMALE","22 Years",{"count":51,"type":21},533,"OBSERVATIONAL","A longitudinal study to investigate the prevalence of sexually transmitted infections among young women and determine the role of the female genital tract microbiome in fertility",[55],"Sexually Transmitted Infection","RECRUITING","2026-04-29",{"date":59,"type":32},"2026-04-30",{"date":61,"type":32},"2020-11-11",{"date":63,"type":21},"2029-06-30",{"name":38,"class":39},1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":4},"100622924","phase-4-semaglutide-prior-to-catheeter-ablation-in-patients-with-atrial-fibrillation-100622924","NCT07389941","Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation","Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation (SPICE-AF)","SPICE-AF","Inclusion criteria:\n\n* Age 18-80 years\n* Symptomatic paroxysmal or persistent AF eligible for first-time catheter ablation\n* Body mass index ≥30 kg\u002Fm or body mass index ≥28 kg\u002Fm plus ≥1 weight-related comorbidity\n* No prior treatment with glucacon-like peptide-1 receptor agonists\n\nExclusion criteria:\n\n* Current use of glucacon-like peptide-1 receptor agonists or dipeptidyl peptidase 4 inhibitors or use within the last 90 days prior to screening\n* Current antiobesity medication use or use within the last 90 days prior to screening\n* A self-reported change in body weight of \\>5 kg within 30 days before screening\n* History of bariatric surgery\n* History of diabetes mellitus\n* Hospitalization for unstable angina, or transient ischemic attack \\\u003C30 days prior to screening\n* Pulmonary embolism \\\u003C90 days before screening\n* Myocardial infarction, or stroke \\\u003C90 days prior to screening\n* Uncontrolled thyroid disease: thyroid-stimulating hormone \\>10.0 mIU\u002FL or \\\u003C0.4 mIU\u002FL at screening\n* Active malignancy\n* Acute pancreatitis \\\u003C180 days before screening\n* History or presence of chronic pancreatitis\n* Chronic kidney disease with creatinine clearance \\\u003C30 mL\u002Fmin\n* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2\n* Chronic inflammatory conditions requiring immunosuppression and\u002For on glucocorticoids\n* Pregnancy, breast-feeding or planning pregnancy",{"count":75,"type":21},240,[77],"PHASE4","To evaluate whether pre-treatment with semaglutide is superior to standard care in improving freedom from atrial fibrillation (AF) at 12 months following catheter ablation in patients with obesity and symptomatic AF undergoing first-time ablation.",[27],"2026-02-08",{"date":82,"type":32},"2026-02-11",{"date":84,"type":21},"2026-10",{"date":86,"type":21},"2029-04",{"name":38,"class":39},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100622923","comprehensive-biomarker-profiling-in-patients-with-ventricular-tachycardia-premature-ventricular-contractions-and-avnrt-100622923","NCT07389928","Comprehensive Biomarker ProfiliNg in PatieNts With VEntriCular TachyCardia, PremAtuRe VEntricular Contractions, and AVNRT","Comprehensive Biomarker ProfiliNg in PatieNts With VEntriCular TachyCardia, PremAtuRe VEntricular Contractions, and AVNRT (CONNECT-CARE)","CONNECT-CARE","Inclusion criteria:\n\n* Age ≥ 18 years\n* Catheter ablation due to VT, PVC, or AVNRT\n* Written informed consent\n\nExclusion criteria:\n\n* Infection or inflammatory disease at time of sampling\n* Pregnancy\n* Inability to comply with study procedures\n* Life expectancy \\\u003C 1 year not due to arrhythmia",{"count":97,"type":21},200,"To systematically evaluate multiple biomarkers in patients ventricular tachycardia (VT), premature ventricular contractions (PVC), atrioventricular nodal reentrant tachycardia (AVNRT) undergoing catheter ablation to elucidate their mechanistic relevance and predictive value.",[100],"Arrhythmia","2026-01-28",{"date":103,"type":32},"2026-02-05",{"date":105,"type":21},"2026-04",{"date":107,"type":21},"2030-10",{"name":38,"class":39},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":48,"minAge":18,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},"100324720","clinical-cohort-study-on-the-endocrinology-and-vaginalendometrial-microbiome-of-the-luteal-phase-in-assisted-reproduction-100324720","NCT03507673","Clinical Cohort Study on the Endocrinology and Vaginal\u002FEndometrial Microbiome of the Luteal Phase in Assisted Reproduction","Prospective, Clinical Cohort Study on the Endocrinology and Vaginal\u002FEndometrial Microbiome of the Luteal Phase and Pregnancy After Embryo Transfer in Assisted Reproduction","Inclusion Criteria:\n\n1. Patients aged 18 to 45 years\n2. Transfer of cryopreserved embryos\n\nExclusion Criteria:\n\n1. Fresh IVF\u002FICSI embryo transfer cycle\n2. Evidence for ovulation on ultrasound previous to embryo transfer confirmed by a follicle ≥14mm or by a progesterone ≥1.0 µg\u002Fl in programmed cycles\n3. Uterus malformations, endometrial abnormalities (on ultrasound or diagnosed by previous hysteroscopy)","45 Years",{"count":118,"type":21},1200,"Rationale:\n\nThe hormone progesterone has different functions. In pregnancy, it is vital for maintenance thereof. In early pregnancy, progesterone is synthesized by the Corpus luteum (CL). Its production shifts from the CL to the placenta after several gestational weeks. This process is termed luteoplacental shift. Still, the exact time point of the luteoplacental shift remains unknown. Furthermore, the characteristics of placental progesterone increase and its relevance for the course of pregnancy has not been studied so far.\n\nFurthermore, recent studies have shown an influence of abnormal vaginal microbiota on the likelihood to achieve and maintain pregnancy. Little is known about possible crosslinks between endocrinology and vaginal\u002Fendometrial microbiota which is why this study aims to investigate possible associations of such kind.\n\nObjective:\n\nThe primary objective of this study is to evaluate the time point of the luteoplacental shift in patients achieving pregnancy after transfer of cryopreserved embryos subsequently to IVF\u002FICSI cycles. Secondary objectives are to study the characteristics of the placental progesterone increase and its function as a predictor of the course and development of pregnancies and to study vaginal\u002Fendometrial microbiota at baseline and changes associated with shift into luteal phase and early pregnancy and how this potentially relates to pregnancy outcome.\n\nStudy Design:\n\nProspective, multi-center, observational clinical cohort study. For the primary objective, data from a single center will be also be retrospectively analyzed.\n\nStudy population:\n\nFemale patients aged 18 to 45 years undergoing transfer of embryos after freezing and thawing 2PN oocytes or embryos.\n\nInterventions: Blood withdrawal, vaginal\u002Fendometrial swabs and endocrine and microbiom analyses.\n\nStudy parameters\u002Fendpoints:\n\nThe main parameter is time point of progesterone increase in pregnancy in relation to initial progesterone levels by pregnancy status. Secondary, slope and magnitude of placental progesterone increase and its relevance as a predictor for the course and development of pregnancies\u002Fbabies. Furthermore, vaginal microbiota of women undergoing embryo transfer and of women in early pregnancy are parameter of this study.",[121],"Infertility","2025-05-21",{"date":124,"type":32},"2025-05-22",{"date":126,"type":32},"2018-05-02",{"date":128,"type":21},"2028-06-30",{"name":38,"class":39},5,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":65},"100562062","same-day-discharge-versus-overnight-stay-following-pulmonary-vein-isolation-for-atrial-fibrillation-100562062","NCT06598280","Same-Day Discharge Versus Overnight Stay Following Pulmonary Vein Isolation for Atrial Fibrillation","Same-Day Discharge Versus Overnight Stay Following Pulmonary Vein Isolation for Atrial Fibrillation - the SHAzAM-AF Study","SHAzAM-AF","Inclusion Criteria:\n\n* Patients age \\>=18 years\n* Elective catheter ablation for atrial fibrillation using 6 to 14 Fr inner diameter introducer sheath with a minimum of 1 and maximum of 2 femoral venous access sites, independent of the energy source use\n\nExclusion Criteria:\n\n* Active systemic or cutaneous infection, or inflammation in vicinity of the groin\n* Platelet count \\\u003C 50,000 cells\u002Fmm3\n* Body mass index (BMI) \\> 45 kg\u002Fm2 or \\\u003C 18 kg\u002Fm2",{"count":140,"type":21},270,[24],"Prospective, randomized, controlled, multicentre study to compare the safety and efficacy of a Same Day Discharge (SDD) protocol in combination with a Perclose ProStyle (PPS) \u002FProGlide (PPG) suture mediated vascular closure device to the current gold standard: an overnight stay (ONS) protocol associated with manual compression ± figure-of-eight suture for the patients receiving interventional pulmonary vein isolation (PVI).",[144],"Atrial Fibrillation","2025-04-04",{"date":147,"type":32},"2025-04-08",{"date":149,"type":32},"2025-02-20",{"date":151,"type":21},"2028-03-15",{"name":38,"class":39},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":65},"100452599","real-world-evidence-on-follitropin-delta-individual-dosing-100452599","NCT05173597","Real-world Evidence on Follitropin Delta Individual Dosing","The Performance of an Individual Dosing Regimen of Follitropin Delta for Controlled Ovarian Stimulation for IVF in a Real-word Setting: a Non-interventional Observational Study","Inclusion Criteria:\n\n* Age ≥18 to ≤ 44 years at enrolment\n\n  * Planned stimulation in a fixed or flexible GnRH antagonist protocol\n  * Planned use of follitropin delta for ovarian stimulation as per SmPC\n  * Planned IVF or ICSI treatment with ejaculated or cryopreserved male germ cells, autologous or heterologous, with or without planned genetic testing of the oocytes or embryos\n  * Planned preservation of MII oocytes (fertility preservation)\n  * Planned triggering of final oocyte maturation with hCG or a GnRH agonist\n  * Willingness and consent to participate\n\nExclusion Criteria:\n\n* Serum AMH within 12 months prior to treatment ≤0.3 ng\u002Fml\n* Most recent serum AMH value before start of stimulation older than 12 months\n* Serum AMH value not determined in Roche Elecsys immunoassays\n* Pre-treatment with a combined oral contraceptive \"pill\" consisting of ethinyl estradiol and a synthetic progestogen","44 Years",{"count":162,"type":21},850,"As part of the in vitro fertilisation treatment, ovarian stimulation is routinely performed. For this purpose, FSH preparations are used. Follitropin delta is a FSH preparation that is approved for a wide range of applications and is dosed individually according to body weight and serum anti-Müllerian hormone (AMH). Body weight is used to estimate the distribution volume of the glycoprotein FD in the patient and is thus a proxy of exposure. The AMH is used to estimate the ovarian reserve and thus the number of follicles in the ovaries that can be recruited by Follitropin delta stimulation. An algorithm is used for individual dosing. The aim of individual dosing is to reduce the probability of an under or overreaction of the ovaries to FSH therapy.\n\nIn contrast to phase III registration studies, patients with severe overweight and underweight, as well as very high and very low AMH values and associated disorders of the menstrual cycle and oocyte maturation, are also found in the reality of care. The performance of the dosing algorithm and thus the results of ovarian stimulation in these subgroups of patients have so far been insufficiently investigated in the phase III registration trials.\n\nIn the present study no statistical hypothesis will be tested. The study is descriptive by design and the analyses are descriptive and exploratory. NIS is chosen in order to explore how the individualized dosing regimen of REKOVELLE® performs in routine clinical practice and to investigate the effectiveness and safety of REKOVELLE® under real-world conditions. This is a monocentric, prospective, non-interventional cohort study conducted in normal care setting in a fertility clinic that will collect information from 850 women undergoing up to two cycles of IVF or ICSI treatment with controlled ovarian stimulation with REKOVELLE®.",[121,165],"Sterility",[167,168,169,170],"In-Vitro-Fertilisation","Assisted reproduction","Ovarian Stimulation","Ovarian Hyperstimulation Syndrome","2025-03-25",{"date":173,"type":32},"2025-03-30",{"date":175,"type":32},"2021-12-08",{"date":177,"type":21},"2026-03",{"name":38,"class":39},{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":65},"100554046","myval-transaxillary-transcatheter-aortic-valve-replacement-multicenter-clinical-registry-100554046","NCT06493994","Myval TransAXillary Transcatheter Aortic Valve Replacement Multicenter Clinical Registry","MYVAL-TAX-TAVR","Inclusion Criteria:\n\n* Patient has been treatet transaxillary (TAX) with Myval transcatheter aortic valve replacement\n* BMI \\\u003C35 kg\u002Fm2\n* Ability to give informed consent\n\nExclusion Criteria:\n\n* History of coronary artery bypass graft and a patent left internal mammary artery (LIMA)\n* Age ≤18 years\n* Patients presenting with pregnancy\n* Patients without informed consent\n* Expected life expectancy \\\u003C2 years",{"count":187,"type":21},100,"Study goal is to determine the feasibility, procedural success, safety and potential benefit of the Myval transcatheter heart valve (THV) in patients undergone transaxillary (TAX) transcatheter aortic valve replacement (TAVR).",[190],"Aortic Valve Stenosis","2025-01-02",{"date":193,"type":32},"2025-01-03",{"date":195,"type":32},"2025-01-01",{"date":197,"type":21},"2027-01-30",{"name":38,"class":39},{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":47,"sex":17,"minAge":18,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":65},"100513376","echocardiography-based-motion-integration-and-management-for-substrate-characterization-and-star-therapy-in-ventricular-tachycardias-100513376","NCT05964660","Echocardiography-based Motion Integration and Management for Substrate Characterization and STAR Therapy in Ventricular Tachycardias","New 3D-echocardiography-based Motion Integration and mAnagement for subsTrate characteRisation and Stereotactic Arrhythmia radIoablation tX in Ventricular Tachycardias- the MATRIX-VT Study","MATRIX-VT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Indication for catheter ablation of ventricular arrhythmias (ventricular fibrillation, ventricular tachycardia, premature ventricular contractions)\n* Indication for preprocedural contrast-enhanced cardiac computed tomography for cardiac structure characterization\n\nExclusion Criteria:\n\n* Platelet count \\\u003C 100,000 cells\u002Fmm3\n* BMI \\> 45 kg\u002Fm2 or \\\u003C 18 kg\u002Fm2","100 Years",{"count":209,"type":21},20,"Prospective, observational, single center, pilot study to analyze the feasibility of motion and structural data integration in patients with ventricular arrhythmia by means of artificial intelligence for improved arrhythmogenic substrate characterization and motion management during stereotactic arrhythmia radioablation.",[212],"Ventricular Arrythmia",[214,215,216,217,218,219],"Ventricular arrhythmia","Ventricular tachycardia","Stereotactic arrhythmia radioablation","Artificial intelligence","Motion management","Motion integration","2024-08-28",{"date":222,"type":32},"2024-08-29",{"date":224,"type":32},"2023-08-14",{"date":226,"type":21},"2025-03",{"name":38,"class":39},{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":241,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":247},"100380959","additional-left-atrial-appendage-isolation-during-balloon-ablation-for-persistent-or-long-standing-persistent-atrial-fibrillation-100380959","NCT04240366","Additional Left Atrial Appendage Isolation During Balloon Ablation for Persistent or Long-standing Persistent Atrial Fibrillation","LALA-LAND-AF","Inclusion Criteria:\n\n1. Persistent or long-standing persistent AF (i.e. continuous AF that was\u002Fis sustained \\>7 days or \\>12 months, respectively)\n2. Age ≥18 and ≤80 years\n3. Indication for AF ablation as per current guidelines\n\nExclusion Criteria:\n\n1. Missing informed consent\n2. LAA diameter \\>25mm 10mm distant from circumflex artery assessed by TEE\n3. Paroxysmal atrial fibrillation\n4. Long-standing persistent atrial fibrillation with a continuous AF duration of \\>4 years\n5. Previous pulmonary vein isolation or MAZE surgery\n6. Previous led atrial appendage closure or surgical excision\n7. Left atrial diameter \\>60 mm at baseline\n8. Left atrial thrombus at baseline",{"count":236,"type":21},350,[24],"Additional left atrial appendage isolation during balloon ablation for persistent or long-standing persistent atrial fibrillation can reduce atrial fibrillation reoccurrence within 3-12 months compared to balloon-based pulmonary vein isolation only.",[240],"Persistent or Long-standing Persistent Atrial Fibrillation",{"date":222,"type":32},{"date":243,"type":32},"2019-12-17",{"date":245,"type":21},"2028-08",{"name":38,"class":39},3,{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":259,"conditions":260,"keywords":262,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":65},"100469226","the-international-subcutaneous-implantable-cardioverter-defibrillator-registry-isusi-100469226","NCT05390047","The International SubcutaneouS Implantable Cardioverter Defibrillator Registry (iSuSI)","The International Subcutaneous Implantable Cardioverter Defibrillator Registry (iSuSi)","iSuSI","Inclusion Criteria:\n\n* Implantation of an S-ICD, regardless of the technique\n* At least 1 month of follow up\n* At least 1 post-implantation assessment, in accordance to the routine clinical practice of every center (e.g. in person visit or remote follow up)\n\nExclusion Criteria:\n\n\\- none","99 Years",{"count":258,"type":21},4000,"The entirely subcutaneous implantable defibrillator (S-ICD) (Emblem, Boston Scientific, Marlborough, MA, USA) was introduced as a new therapeutic alternative to the conventional transvenous ICD in 2009 and implantations are rapidly expanding since then.1 Implantation of the S-ICD seems to reduce implant-related perioperative complications such as pneumothorax, hematoma and cardiac tamponade.\n\nThe aim of this multicenter registry is thus to assess the outcome of patients following an S-ICD implantation in a real-world setting.",[261],"Sudden Cardiac Death",[263],"subcutaneous implantable cardioverter defibrillator","2024-06-28",{"date":266,"type":32},"2024-07-01",{"date":268,"type":32},"2022-07-01",{"date":270,"type":21},"2025-09-30",{"name":38,"class":39},""]